Large in-frame 5′ deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature

[1]  S. Nelson,et al.  DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype , 2018, Human mutation.

[2]  S. Nelson,et al.  Validation and Detection of Exon Skipping Boosters in DMD Patient Cell Models and mdx Mouse. , 2018, Methods in molecular biology.

[3]  Malte Tiburcy,et al.  Functional correction of dystrophin actin binding domain mutations by genome editing. , 2017, JCI insight.

[4]  E. Hoffman,et al.  P.103 DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study , 2016, Neuromuscular Disorders.

[5]  A. Nakamura,et al.  Deletion of exons 3−9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy , 2016, Journal of Human Genetics.

[6]  I. Szijan,et al.  MLPA analysis of an Argentine cohort of patients with dystrophinopathy: Association of intron breakpoints hot spots with STR abundance in DMD gene , 2016, Journal of the Neurological Sciences.

[7]  Atsushi Nakano,et al.  A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. , 2016, Cell stem cell.

[8]  K. Bushby,et al.  The importance of genetic diagnosis for Duchenne muscular dystrophy , 2016, Journal of Medical Genetics.

[9]  G. Butler-Browne,et al.  Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients’ Cells , 2015, Journal of neuromuscular diseases.

[10]  E. McNally,et al.  The Dystrophin Complex: Structure, Function, and Implications for Therapy. , 2015, Comprehensive Physiology.

[11]  M. Uhlén,et al.  Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice , 2014, Nature Medicine.

[12]  H. Kan,et al.  Dystrophin levels and clinical severity in Becker muscular dystrophy patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  S. Nelson,et al.  Dantrolene Enhances Antisense-Mediated Exon Skipping in Human and Mouse Models of Duchenne Muscular Dystrophy , 2012, Science Translational Medicine.

[14]  J. Ervasti,et al.  Internal deletion compromises the stability of dystrophin. , 2011, Human molecular genetics.

[15]  S. Singh,et al.  Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-β aggregates , 2010, Proceedings of the National Academy of Sciences.

[16]  Zhujun Zhang,et al.  Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center , 2010, Journal of Human Genetics.

[17]  J. Ervasti,et al.  Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation , 2010, Proceedings of the National Academy of Sciences.

[18]  S. Pandya,et al.  Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. , 2009, MMWR. Morbidity and mortality weekly report.

[19]  D. Marzese,et al.  Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion , 2009, Muscle & nerve.

[20]  T. Frieden,et al.  Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. , 2009, MMWR. Morbidity and mortality weekly report.

[21]  S. Tapscott,et al.  Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. , 2008, Human molecular genetics.

[22]  G. Piluso,et al.  Log-PCR: a new tool for immediate and cost-effective diagnosis of up to 85% of dystrophin gene mutations. , 2008, Clinical chemistry.

[23]  J. Chamberlain,et al.  Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. , 2007, Human molecular genetics.

[24]  G. van Ommen,et al.  Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.

[25]  Dejan Stefanović,et al.  Proximal Dystrophin Gene Deletions and Protein Alterations in Becker Muscular Dystrophy , 2005, Annals of the New York Academy of Sciences.

[26]  J. Ervasti,et al.  Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. , 2002, Human molecular genetics.

[27]  J. T. Dunnen,et al.  Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family , 2000, European Journal of Human Genetics.

[28]  J. Faulkner,et al.  Transgenic mdx mice expressing dystrophin with a deletion in the actin- binding domain display a "mild Becker" phenotype , 1996, The Journal of cell biology.

[29]  P. Ray,et al.  A novel dystrophin isoform is required for normal retinal electrophysiology. , 1995, Human molecular genetics.

[30]  H. Jarrett,et al.  Alternate Binding of Actin and Calmodulin to Multiple Sites on Dystrophin , 1995, The Journal of Biological Chemistry.

[31]  J. Mendell,et al.  Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production. , 1995, American journal of human genetics.

[32]  K. Bushby,et al.  Becker muscular dystrophy with onset after 60 years , 1994, Neurology.

[33]  F. Muntoni,et al.  Deletions in the 5' region of dystrophin and resulting phenotypes. , 1994, Journal of medical genetics.

[34]  M Bobrow,et al.  Searching for the 1 in 2,400,000: A review of dystrophin gene point mutations , 1994, Human mutation.

[35]  J. Ervasti,et al.  A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin , 1993, The Journal of cell biology.

[36]  J. Mendell,et al.  Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy , 1993 .

[37]  H Sugita,et al.  Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. , 1991, American journal of human genetics.

[38]  C. Caskey,et al.  Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies , 1989, Neurology.

[39]  M. W. Thompson,et al.  Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. , 1988, Science.